Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Second Quarter 2012 Results


      News provided by

      Cambrex Corporation

      Aug 01, 2012, 04:07 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Aug. 1, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports second quarter results for the period ended June 30, 2012.

      Highlights

      • Reported sales increased by 14.3%, and excluding the impact of foreign currency, sales increased 20.2% compared to the second quarter of 2011. 
      • EBITDA increased 45.9% to $19.2 million in the quarter, compared to $13.2 million in the second quarter of 2011. 
      • Debt, net of cash was $58.2 million at the end of the quarter, an improvement of $5.1 million during the quarter which includes a negative $1.1 million currency impact on foreign cash balances.
      • Full year sales guidance, excluding the impact of foreign currency, revised to an increase of between 10% and 13% versus 2011 (prior guidance between 2% and 6%) and full year EBITDA guidance revised to be between $54 and $58 million (prior guidance between $47 and $53 million).

      Second Quarter of 2012 Operating Results
      Sales in the second quarter of 2012 of $77.1 million were 14.3% higher than the second quarter of 2011.  Foreign exchange unfavorably impacted sales by 5.9%.  The increase is primarily due to higher volumes of controlled substances and generic active pharmaceutical ingredients ("APIs").

      Gross margins in the second quarter of 2012 increased to 36.9% from 28.2% in the second quarter of 2011.  Foreign currency favorably impacted second quarter 2012 margins by 1.5%.  The increase is due to higher production volumes, leading to increased plant efficiencies and favorable product mix. 

      Selling, General and Administrative Expenses in the second quarter of 2012 were $12.0 million compared to $9.2 million in the same period last year.  The increase is primarily the result of increased personnel related expenses, accruals for higher annual incentive awards, higher expenses related to stock-based compensation as a result of the Company's higher stock price, and higher medical expenses and professional fees.

      Operating Profit increased to $13.9 million in the second quarter of 2012 from $7.3 million in the second quarter of 2011.  As described above, increased profits, primarily driven by higher sales volumes, were partially offset by lower pricing and higher operating expenses.

      Net Interest Expense increased to $0.7 million in the second quarter of 2012 from $0.6 million in the same period last year.  This increase is primarily due to higher average interest rates partially offset by lower average debt in the second quarter of 2012.  The average interest rate on debt was 2.3% in the second quarter of 2012 versus 1.5% in the second quarter of 2011. 

      Equity in Losses of Partially-Owned Affiliates includes $0.4 million and $0.3 million in the second quarters of 2012 and 2011, respectively, for the Company's share of losses in Zenara Pharma, a pharmaceutical company focused on the formulation of finished dosage form products.  Cambrex owns a 51% stake in Zenara.  The Company's share of Zenara's losses includes $0.2 million and $0.3 million of amortization expense in the second quarters of 2012 and 2011, respectively.

      The Provision for Income Taxes totaled $2.9 million and resulted in an effective tax rate of 22.5% in the second quarter of 2012.  The effective tax rate improved during the quarter due to an increase in profitability in the U.S. where the Company is able to utilize tax attributes to offset domestic tax expense.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income.

      Net Income for the second quarter of 2012 was $9.9 million or $0.33 per share compared to $4.8 million or $0.16 per share in the second quarter of 2011.

      Capital expenditures and depreciation for the second quarter of 2012 were $4.3 million and $5.3 million, respectively, compared to $3.0 million and $5.8 million in the second quarter of 2011, respectively.

      Steven M. Klosk, President and Chief Executive Officer, said, "We are very pleased with our second quarter performance, with another quarter of strong sales and profit growth across most of our product categories.  The first half of the year, fueled by strong sales of controlled substances and generic APIs, is the best operating performance that we have achieved in several years.  We are encouraged by the pipeline of opportunities, especially in the U.S. market, and continue to see strong orders for our generic products.  While the second half of 2012 will not be as strong as the first half, I remain optimistic that we are well positioned to continue the growth that we are currently experiencing."

      Guidance – Continuing Operations
      The Company expects that full year 2012 sales, excluding the impact of foreign currency, will increase between 10% and 13% versus 2011, and that full year 2012 EBITDA will be between $54 and $58 million.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The above guidance does not reflect Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results.  Cambrex's income statement reflects 51% of Zenara's net results within Equity in Losses of Partially-Owned Affiliates.  For 2012, the Company continues to expect Zenara to have revenues in the low single digit millions and a small EBITDA loss.

      Capital expenditures are expected to be approximately $16 to $19 million and depreciation is expected to be $21 to $23 million in 2012.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's second quarter 2012 Form 10-Q is filed with the SEC.

      Conference Call and Webcast
      The Conference Call to discuss second quarter results will begin at 8:30 a.m. Eastern Time on Thursday, August 2, 2012 and last approximately 45 minutes.  Those wishing to participate should call 1-888-312-9841 for domestic and +719-325-2423 for international.  Please use the pass code 4333709 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Thursday, August 9, 2012 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 4333709 to access the replay. 

      Forward Looking Statements
      This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Guidance – Continuing Operations," including the Company's expectation that full year 2012 sales, excluding the impact of foreign currency, will increase between 10% and 13% versus 2011, that full year 2012 EBITDA will be between $54 and $58 million, that Zenara will have revenues in the low single digit millions and a small EBITDA loss, that capital expenditures will be approximately $16 to $19 million and that depreciation will be $21 to $23 million in 2012.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2011, captioned "Risk Factors," or otherwise described in the Company's filings with the Securities and Exchange Commission, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2011, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, governmental legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2011, including the Forward-Looking Statement sections therein, and other filings with the U.S. Securities and Exchange Commission. 

      Use of Non-GAAP Financial Measures
      EBITDA is a non-GAAP financial measure, which the Company defines as operating profit plus depreciation and amortization expense.  Other companies may have a different definition of EBITDA and, therefore, EBITDA may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA as one of several metrics to assess and analyze its operational results and trends.  Cambrex also believes it is useful to investors because it is a common operating performance metric as well as a metric routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation from U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      About Cambrex
      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended June 30, 2012 and 2011

      (in thousands, except per-share data)













      2012



      2011





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      77,142




      $

      67,484



           Commissions, Allowances and Rebates


      781





      523



      Net Sales


      76,361





      66,961













           Other


      772





      1,421













      Net Revenues


      77,133





      68,382













           Cost of Goods Sold


      48,688


      63.1%



      49,325


      73.1%











      Gross Profit


      28,445


      36.9%



      19,057


      28.2%











      Operating Expenses










           Selling, General and Administrative Expenses


      11,959


      15.5%



      9,191


      13.6%

           Research and Development Expenses


      2,592


      3.4%



      2,572


      3.8%

      Total Operating Expenses


      14,551


      18.9%



      11,763


      17.4%











      Operating Profit


      13,894


      18.0%



      7,294


      10.8%











      Other Expenses/(Income):










           Interest Expense, net


      678





      605



           Other Expenses/(Income), net


      16





      (282)



           Equity in Losses of Partially-Owned Affiliates


      383





      303













      Income Before Income Taxes


      12,817


      16.6%



      6,668


      9.9%











           Provision for Income Taxes


      2,889





      1,911













      Net Income

      $

      9,928


      12.9%


      $

      4,757


      7.0%











      Earnings per Share of Common Stock:










           Basic

      $

      0.34




      $

      0.16



           Diluted

      $

      0.33




      $

      0.16













      Weighted Average Shares Outstanding










           Basic


      29,623





      29,419



           Diluted


      29,912





      29,493



      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Six Months Ended June 30, 2012 and 2011

      (in thousands, except per-share data)













      2012



      2011





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      147,701




      $

      129,138



           Commissions, Allowances and Rebates


      1,316





      814



      Net Sales


      146,385





      128,324













           Other


      976





      643













      Net Revenues


      147,361





      128,967













           Cost of Goods Sold


      96,488


      65.3%



      92,455


      71.6%











      Gross Profit


      50,873


      34.4%



      36,512


      28.3%











      Operating Expenses










           Selling, General and Administrative Expenses


      21,919


      14.8%



      18,279


      14.2%

           Research and Development Expenses


      4,950


      3.4%



      5,632


      4.4%

      Total Operating Expenses


      26,869


      18.2%



      23,911


      18.5%











      Operating Profit


      24,004


      16.3%



      12,601


      9.8%











      Other Expenses/(Income):










           Interest Expense, net


      1,329





      1,178



           Other Expenses/(Income), net


      24





      (285)



           Equity in Losses of Partially-Owned Affiliates


      591





      667













      Income Before Income Taxes


      22,060


      14.9%



      11,041


      8.5%











           Provision for Income Taxes


      5,094





      3,429













      Income from Continuing Operations

      $

      16,966


      11.5%


      $

      7,612


      5.9%











      Loss from Discontinued Operations, Net of Tax


      -





      (146)













      Net Income

      $

      16,966


      11.5%


      $

      7,466


      5.8%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.57




      $

      0.26



         Loss from Discontinued Operations, Net of Tax

      $

      -




      $

      (0.01)



         Net Income

      $

      0.57




      $

      0.25













      Diluted Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.57




      $

      0.26



         Loss from Discontinued Operations, Net of Tax

      $

      -




      $

      (0.01)



         Net Income


      0.57




      $

      0.25













      Weighted Average Shares Outstanding










           Basic


      29,612





      29,433



           Diluted


      29,892





      29,490













      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of June 30, 2012 and December 31, 2011

      (in thousands)

















      June 30,



      December 31,


      Assets


      2012



      2011









      Cash and Cash Equivalents

      $

      21,827


      $

      31,921


      Trade Receivables, net


      43,517



      36,510


      Inventories, net


      67,337



      62,095


      Prepaid Expenses and Other Current Assets


      7,790



      6,083


        Total Current Assets


      140,471



      136,609









      Property, Plant and Equipment, net


      133,730



      139,628


      Goodwill


      35,938



      36,731


      Intangible Assets, net


      4,025



      4,261


      Investments in and Advances to Partially-Owned Affiliates


      15,573



      15,090


      Other Non-Current Assets


      3,125



      3,425









        Total Assets

      $

      332,862


      $

      335,744









      Liabilities and Stockholders' Equity














      Accounts Payable

      $

      21,659


      $

      21,200


      Accrued Expenses and Other Current Liabilities


      40,999



      37,933


        Total Current Liabilities


      62,658



      59,133









      Long-term Debt


      80,000



      98,000


      Deferred Income Taxes


      16,044



      16,243


      Accrued Pension and Postretirement Benefits


      49,664



      52,089


      Other Non-Current Liabilities


      9,652



      9,938









        Total Liabilities

      $

      218,018


      $

      235,403









        Stockholders' Equity

      $

      114,844


      $

      100,341









        Total Liabilities and Stockholders' Equity

      $

      332,862


      $

      335,744









      CAMBREX CORPORATION

      Reconciliation of EBITDA

      For the Quarters and Six Months Ended June 30, 2012 and 2011

      (in thousands)









      Second Quarter 2012



      Second Quarter 2011








      Operating Profit

      $

      13,894



      $

      7,294








      Depreciation and Amortization


      5,324




      5,878








      EBITDA

      $

      19,218



      $

      13,172


























































      Six Months 2012



      Six Months 2011








      Operating Profit

      $

      24,004



      $

      12,601








      Depreciation and Amortization


      10,810




      11,603








      EBITDA

      $

      34,814



      $

      24,204








      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.